Location
Moultrie, GA
Start Date
7-5-2025 1:00 PM
End Date
7-5-2025 4:00 PM
Description
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective treatments for type 2 diabetes mellitus and obesity. While these medications are known to delay gastric emptying, the relationship between the minimum dosage needed to develop clinically significant gastroparesis remains to be further investigated.
Objective: To investigate and establish the dose-dependent relationship between GLP-1 therapies and the incidence or severity of gastroparesis. Furthermore, we seek to identify the common potential dosage in which this adverse effect occurs.
Methods: This research seeks to utilize a systematic review and meta-analysis approach to investigate the dose-dependent relationship between GLP-1 receptor agonists (GLP-1 RAs) and the development of gastroparesis. The methodology we seek to adhere to is outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies published in reputable journals will be pooled for our analysis if they: involved human subjects, evaluated at least one GLP-1 RA, reported dosage information, assessed gastroparesis or delayed gastric emptying using validated methods, and provided data on the relationship between dosage and gastroparesis development.
Results and Conclusions: Following the results displayed in statistical analysis performed, this study hopes to identify a common minimal dosage among GLP-1s that correlates to the onset of gastroparesis. Further research will be needed to develop actionable interventions and management strategies for diabetic and obese patients when it comes to the correlation between gastroparesis and GLP-1s.
Embargo Period
6-4-2025
Included in
Determining Minimal Dosage Thresholds for Gastroparesis Development in GLP-1 Receptor Agonist Therapy: A Comprehensive Systematic Review and Meta-Analysis
Moultrie, GA
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective treatments for type 2 diabetes mellitus and obesity. While these medications are known to delay gastric emptying, the relationship between the minimum dosage needed to develop clinically significant gastroparesis remains to be further investigated.
Objective: To investigate and establish the dose-dependent relationship between GLP-1 therapies and the incidence or severity of gastroparesis. Furthermore, we seek to identify the common potential dosage in which this adverse effect occurs.
Methods: This research seeks to utilize a systematic review and meta-analysis approach to investigate the dose-dependent relationship between GLP-1 receptor agonists (GLP-1 RAs) and the development of gastroparesis. The methodology we seek to adhere to is outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies published in reputable journals will be pooled for our analysis if they: involved human subjects, evaluated at least one GLP-1 RA, reported dosage information, assessed gastroparesis or delayed gastric emptying using validated methods, and provided data on the relationship between dosage and gastroparesis development.
Results and Conclusions: Following the results displayed in statistical analysis performed, this study hopes to identify a common minimal dosage among GLP-1s that correlates to the onset of gastroparesis. Further research will be needed to develop actionable interventions and management strategies for diabetic and obese patients when it comes to the correlation between gastroparesis and GLP-1s.
Comments
Presented by Kenyot'a Russell.